Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide vs Flutamide in CRPC after Bicalutamide
NCT02346578Phase 2Completed
- Start
- Dec 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzalutamide in castration-resistant prostate cancer (CRPC). Primary endpoint: Prostate Specific Antigen 50 Percent Decrease at Month 3. Started Dec 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02346578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346578.